Tamoxifen generics

Executive Summary

Seven generic manufacturers are approved to launch tamoxifen (equivalent to AstraZeneca's Nolvadex) on Feb. 21. Barr, which marketed an "authorized" generic for a decade until the agreement expired in August, is among those with approved ANDAs. AstraZeneca is already marketing its own generic version (1"The Pink Sheet" Feb. 3, p. 13). Ivax, Mylan, Teva and Roxane Labs 10 mg tablets (60-count) will be priced at $113.10 to $113.77 AWP. AstraZeneca AWP for the generic is $116.98, while branded Nolvadex carries an AWP of $126.41, according to First DataBank's Price Alert. Barr says its price will be below what it offered under the AstraZeneca licensing deal ($121.59 AWP). Andrx also received approval, but says it has no plans to launch due to the number of competitors...